AniLocus Inc. | In Vivo CRO

  • No products in the cart.

Preclinical In Vivo Contract Research Services Contact Us!
AniLocus   →  Our Services   →  Allergy & Inflammation

Allergy & Inflammation

AniLocus | Allergy Preclinical CRO | Inflammation Preclinical CRO | Hypersensitivity

AniLocus | Preclinical CRO | Lung Disease, Respiratory Disease, Lung Cancer, Lung Infections, COPD, Mesenchymal Stem Cell, Respiratory Medical Devices
Preclinical CRO Services

Speak with a Scientist Today!

Schedule a consult today and let's discuss how AniLocus can advance your product from Bench-to-Market.

Make an Appointment

Allergies & Inflammation are immune system disorders and symptoms triggered by reactions to antigens.  How our body responds in a normal or exaggerated response to antigens is cause for the significance of understand how to treat immune response related disorders with novel therapeutics.

At AniLocus, we provide your team with standard and customizable preclinical models to validate the efficacy and safety of allergy-related drug/device therapeutics.

We can develop experimental design, IACUC protocols, model selection, model induction, targeting studies, microosmotic drug infusion, behavioral assessments, histopathology, immunohistochemistry, serology, toxicity, tolerability, data analysis, acute and long-term efficacy and safety, and toxicology dosing studies for translational drug delivery/administration routes.

Worldwide Allergy & Immune Disorder Prevalence*

  • Food Allergies – ≥4% adults and children
  • Anaphylaxis – 0.25% of hospitalizations)
  • Allergic bronchopulmonary aspergillosis (ABPA) – 4.8 million people)
  • Asthma (Childhood, Exercise-Induced, Adulthood, Occupational) – 260 million people
  • Chronic Cough – 9.6% of population)
  • Chronic Granulomatous Disease – 1:250,000 people
  • Chronic Sinusitis – 28 million people
  • Churg-Strauss Syndrome – 11:1,000,000 people
  • Common Variable Immunodeficiency – 1:25,000 people
  • Conjunctivitis – ~6 million, United States
  • Contact Dermatitis – 5.7 million people
  • Drug Allergy – 10% of population
  • Environmental/Seasonal Allergies – 30% of total world population
  • Eosinophilic Esophagitis – 1:1,000 people
  • Eczema – 30 million people
  • Hay fever – 30% of world population
  • Urticaria and Angioedema – 86 million people

Note (*): Estimated number and/or percentage of adults and children diagnosed worldwide.

Contact us to learn more about our preclinical solutions for your product development.

Multiple animal models are used in preclinical product development for allergy and immune disorder therapies including:

  • Gene knockout/knockin/trapped
  • Allergy Rodent Models
  • Immunodeficiency Rodent Models
  • Transgenic rodents
  • Chemically-Induced Point Mutation rodents
  • Stress-induced models
  • Drug-Induced models
  • Wound/Laceration Models
  • Metabolic Dysfunction Models (Diet-induced, Metabolic disorder, micronutrient deficient)
  • And more…

We conduct translational in vivo animal studies collecting detailed, comprehensive results with rapid turnaround.

Drug modalities are different types of therapeutic agents. Each drug is a customizable tool designed for therapeutic intervention. The question is…does your product work and is it safe?

At AniLocus, we conduct relevant preclinical studies to validate any drug modality:

  • Antibodies (nanobodies, monoclonal)
  • Gene therapy (CRISPR, TALEN)
  • Viral therapy (adenovirus-AAV, lentivirus)
  • Oligo- and polypeptides (e.g., stapled and modified peptides)
  • Oligo- and polynucleotides (e.g., siRNAs, mRNAs, aptamers)
  • Polyglycosides
  • Macrocyclic molecules
  • Drug conjugates (e.g., antibody–drug conjugates, drug–drug conjugates, fluorescence-labeled drugs)
  • Targeted protein degraders (e.g., proteolysis-targeting chimeras (PROTACs) and molecular glues) that induce a chemical knockdown of proteins
  • Cellular therapies (stem cells, allogenic, autologous)

We can perform multiple interrogative assays for any therapeutic area and sample type:

  • DNA: Extraction, PCR, ddPCR, qPCR, sequencing, genotyping
  • RNA: Gene expression profiling, RT-PCR, miRNA, Next-generation sequencing (Nanostring, Illumina), spatial transcriptomics, In situ hybridization (ISH), Multiplex ISH
  • Protein: Immunoassays (ELISA, EIA, Luminex), proteomics, ligand binding assays, protein expression, immunohistochemistry (IHC), immunocytochemistry (ICC), and  immunofluorescence (IF)
  • And more!
  1. Stevens, D. A., Moss, R. B., Kurup, V. P., Knutsen, A. P., Greenberger, P., Judson, M. A., Denning, D. W., Crameri, R., Brody, A. S., Light, M., Skov, M., Maish, W., Mastella, G., & Participants in the Cystic Fibrosis Foundation Consensus Conference (2003). Allergic bronchopulmonary aspergillosis in cystic fibrosis–state of the art: Cystic Fibrosis Foundation Consensus Conference. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 37 Suppl 3, S225–S264. https://doi.org/10.1086/376525.
  2. Schülke, S., & Albrecht, M. (2019). Mouse Models for Food Allergies: Where Do We Stand?. Cells, 8(6), 546. https://doi.org/10.3390/cells8060546.
  3. Teng, F., Tachó-Piñot, R., Sung, B., Farber, D. L., Worgall, S., Hammad, H., Lambrecht, B. N., Hepworth, M. R., & Sonnenberg, G. F. (2021). ILC3s control airway inflammation by limiting T cell responses to allergens and microbes. Cell reports, 37(8), 110051. https://doi.org/10.1016/j.celrep.2021.110051
  4. Akkoc, T., O’Mahony, L., Ferstl, R., Akdis, C., & Akkoc, T. (2022). Mouse Models of Asthma: Characteristics, Limitations and Future Perspectives on Clinical Translation. Advances in experimental medicine and biology, 1376, 119–133. https://doi.org/10.1007/5584_2021_654
  5. Takeda, K., & Gelfand, E. W. (2009). Mouse models of allergic diseases. Current opinion in immunology, 21(6), 660–665. https://doi.org/10.1016/j.coi.2009.09.005.
  6. Lee, J. H., Kang, S. Y., Yoo, Y., An, J., Park, S. Y., Lee, J. H., Lee, S. E., Kim, M. H., Kanemitsu, Y., Chang, Y. S., & Song, W. J. (2021). Epidemiology of adult chronic cough: disease burden, regional issues, and recent findings. Asia Pacific allergy, 11(4), e38. https://doi.org/10.5415/apallergy.2021.11.e38.
  7. Chakraborty RK, Aeddula NR. Churg Strauss Syndrome. [Updated 2022 May 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537099/
  8. Xue Y, Bao W, Zhou J, Zhao Q-L, Hong S-Z, Ren J, Yang B-C, Wang P, Yin B, Chu C-C, Liu G and Jia C-Y (2022) Global Burden, Incidence and Disability-Adjusted Life-Years for Dermatitis: A Systematic Analysis Combined With Socioeconomic Development Status, 1990–2019. Front. Cell. Infect. Microbiol. 12:861053. doi: 10.3389/fcimb.2022.861053. https://www.frontiersin.org/articles/10.3389/fcimb.2022.861053/full
Need some advice from our experts?

Contact Us!

Send us a message or schedule a consultation today.

Together, we will discuss your research needs and generate a preclinical service proposal for your immediate review.

Contact